| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SMYD5 |
| Uniprot No | Q6GMV2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-418 aa |
| 活性数据 | MSMCDVFS FCVGVAGRAR VSVEVRFVSS AKGKGLFATQ LIRKGETIFV ERPLVQFL WNALYRYRAC DHCLRALEKA EENAQRLTGK PGQVLPHPEL CTVRKDLHQN CPHCQVMYCS AECRLTEQ YHQVLCPGPS QDDPLHPLNK LQEAWRSIHY PPETASIMLM ARMVATVKQA KDKDRWIRLF SQFCNKTANE EEEIVHKLLG DKFKGQLELL RRLFTEALYE EAVSQWFTPD GFRSLFALVG TNGQGIGTSS LSQWVHACDT LELKPQDREQ LDAFIDQLYK DIETGEFL NCEGSGLFVL QSCCNHSCVP NAETSFPENN FLLHVTALED IKPGEEICIS YLDCCQRERS RHSRHKILRE NYLFVCSCPK CLAEADEPNV TSEEEEEEEE EEEGEPEDAE LGDEMTDV |
| 分子量 | 47.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人SMYD5蛋白的3篇参考文献示例(注：文献为虚拟示例，仅供参考)：
1. **标题**：*Structural and functional characterization of the methyltransferase SMYD5*
**作者**：Zhang Y. et al.
**摘要**：该研究通过重组表达人源SMYD5蛋白，解析了其晶体结构，揭示了该蛋白特有的催化结构域构象，并证明其对组蛋白H3K36位点具有特异性甲基转移酶活性，提示其在染色质修饰中的潜在作用。
2. **标题**：*SMYD5 regulates inflammatory responses via chromatin remodeling*
**作者**：Smith J.P. et al.
**摘要**：利用重组SMYD5蛋白进行体外实验，发现其通过与染色质重塑复合物相互作用，调控巨噬细胞中促炎基因(如IL-6)的表达，表明SMYD5可能在先天免疫中发挥表观遗传调控功能。
3. **标题**：*High-throughput screening identifies SMYD5 inhibitors for cancer therapy*
**作者**：Lee H. et al.
**摘要**：通过重组SMYD5蛋白建立高通量筛选平台，发现小分子抑制剂可阻断其甲基转移酶活性，并在白血病模型中验证了抑制剂对癌细胞增殖的抑制作用，为靶向SMYD5的抗癌策略提供依据。
(注：以上文献信息为示例性质，实际引用请通过PubMed、Web of Science等数据库核实真实研究。)
SMYD5. a member of the SMYD (SET and MYND domain-containing) protein family, is a lysine methyltransferase implicated in epigenetic regulation. Structurally, it contains a conserved N-terminal SET domain responsible for its enzymatic activity, a central MYND domain mediating protein-DNA or protein-protein interactions, and a C-terminal region with potential regulatory roles. Unlike other SMYD members (e.g., SMYD2/3), SMYD5 preferentially methylates non-histone targets, including chromatin-modifying enzymes and transcription factors, influencing gene expression and chromatin dynamics.
Functionally, SMYD5 participates in diverse cellular processes. Studies link it to hematopoietic stem cell maintenance, immune response modulation (e.g., macrophage polarization), and cell cycle regulation. Its aberrant expression correlates with pathologies, particularly hematological malignancies and solid tumors, though its precise oncogenic or tumor-suppressive roles remain context-dependent. SMYD5 also interacts with Polycomb repressive complexes, suggesting crosstalk between methylation-mediated epigenetic pathways.
Recombinant human SMYD5 protein is widely used to study its substrate specificity, enzymatic mechanisms, and structural characteristics. However, research challenges persist, including identifying its physiological substrates and resolving conflicting reports about its nuclear vs. cytoplasmic localization. Current investigations aim to clarify SMYD5's role in development and disease, exploring its potential as a therapeutic target. Its unique substrate preference positions SMYD5 as a critical regulator of non-histone methylation events, distinguishing it within the SMYD family.
×
